Gilteritinib (ASP2215) is a potent, ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM and 0.73 nM, respectively. It inhibits wild-type and mutant FLT3, including FLT3-ITD and FLT3-TKD variants, as well as Axl and c-Kit. Gilteritinib reduces the viability of blast cells from relapsed AML patients and is used in AML treatment. Reagent grade, for research purpose.
Usually ships within 24 hours.